ABSTRACT
With the publication of numerous studies about vitamin D status, interest in vitamin D has increased significantly among both the general public and the medical community.
1,2 As a result, the demand for vitamin D measurement has increased steadily.
There are two main forms of vitamin D in the human body: ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ). Both can be absorbed through food, but vitamin D 3 is also synthesized in the skin when exposed to ultraviolet light. 3 Vitamin D is metabolized to 25-hydroxyvitamin D (25(OH)D) in the liver and then becomes an active form of 1,25-dihydroxyvitamin D (1,25(OH) 2 D) in the kidney. Because 1,25(OH) 2 D has an approximately 1,000 times lower concentration than 25(OH)D and a short half-life, vitamin D deficiency is diagnosed by the concentration of 25(OH)D, which has a relatively larger amount in human serum and a longer half-life of about 2 to 3 weeks. 3, 4 The World Health Organization defines vitamin D deficiency as a 25(OH)D concentration below 10 ng/mL, and below 20 ng/mL is considered insufficient. 5 Total vitamin D is often measured by chemiluminescent immunoassays, which are fully automated and have fast assay speeds with a wide measurement range. 6 However, these assays are based on immunologic principles using antibodies, so cross-reactivities among various forms of vitamin D metabolites can result in differences, depending on the measurement equipment and reagents. 7, 8 Recently, the National Institute of Standards and Technology (NIST) produced new reference material (Standard Reference Material [SRM] 972a and 2972a) to reduce the differences between these vitamin D assays, and it is expected to help in the standardization of various vitamin D assays with different results. 4, [9] [10] [11] In 2015, Abbott launched the new version of the ARCHITECT 25-OH Vitamin D 5P02 assay (Abbott Diagnostics, Abbott Park, IL), and this assay has adopted the same competitive method as the previous version (product number 3L52) but with improved binding activity and stability of the antibody to vitamin D. 4 In addition, the newly introduced calibrator has been standardized against NIST SRM 2972a. The correlation between the ARCHITECT 25-OH Vitamin D 5P02 assay and the reference method (isotope dilution-liquid chromatography-tandem mass spectrometry [ID-LC/MS/MS]) has been verified. 12 This restandardized assay showed excellent analytical performance in various recent literatures. 4, 13, 14 However, no research has been conducted on the Asian population and evaluated measurement uncertainty according to the international guidelines.
In this study, we compared the restandardized ARCHITECT 25-OH Vitamin D assay with other immunoassays using serum samples from the Korean population and quantified the measurement uncertainties using the adequate standard reference material according to the guidelines provided by the Clinical and Laboratory Standards Institute (CLSI) and EURACHEM/CITAC, which is a network of organizations focused on analytical quality in Europe. 
Materials and Methods

Total
Samples
The study included 300 healthy participants who visited Chung-Ang University Hospital for a routine health checkup. Serum samples were collected at Chung-Ang University Hospital between July 2016 and June 2017. This study was approved by the Institutional Review Board of Chung-Ang University Hospital (IRB No. C23016018).
After informed consent was obtained from participants, blood samples were drawn, centrifuged, separated, and divided into five aliquots in 2 hours. One of the aliquots was used for routine clinical measurement of vitamin D, and the rest of the aliquots were stored at -70°C for further vitamin D measurement.
For the evaluation of commutability and trueness, we selected 25 serum samples and used Standard Reference Material 972a (SRM 972a) as a reference material with certified vitamin D values.
11 SRM 972a (NIST, Gaithersburg, MD) consisted of four vials of different total vitamin D concentrations: level 1 (L1), 29.3 ng/mL; level 2 (L2), 18.9 ng/mL; level 3 (L3), 33.2 ng/mL; and level 4 (L4), 30.0 ng/mL.
Study Design
For the comparison analysis of three immunoassays, we prepared samples with as wide of a range as possible. To select adequate reference materials for quantitation of the measurement uncertainty, a two-step approach was done according to CLSI guidelines. First, we evaluated the commutability between reference materials and user measurements. 16 We analyzed 25 human serum samples as a single analytical batch with three immunoassays and ID-LC/MS/MS. Then, the four levels of SRM 972a were assayed with three immunoassays and ID-LC/MS/ MS over 3 days with two replicates per run. The results of three immunoassays were compared against the results of the reference method (ID-LC/MS/MS) using Deming regression analysis, and the commutability of SRM 972a was verified if the measured results were included in the 95% prediction interval of Deming regression lines.
Second, the trueness verification was determined if the observed mean of SRM 972a using immunoassays was within the verification interval according to CLSI guideline EP15-A3. 17 In trueness verification, bias was a measure of trueness, and we verified whether it was the difference between the test result and the accepted reference value. Briefly, the verification interval was calculated from the combined standard error, which was obtained from precision profiles and the uncertainty of the SRM 972a. If the observed mean fell outside of the verification interval, the bias was considered statistically significant.
To quantify the measurement uncertainties of three vitamin D immunoassays, the uncertainties were calculated according to EURACHEM/CITAC guide CG4:
Quantifying Uncertainty in Analytical Measurement. 18 The evaluation of the different effects was considered for quantifying the measurement uncertainties, as well as precision, bias, and uncertainty of SRM 972a. The precision of the analytical procedure was determined with the results of SRM 972a measurement procedures. The results of all duplicate tests with SRM 972a were normalized (the difference divided by the mean), and the standard deviations of the normalized difference were divided by 2 to obtain the estimated relative standard uncertainties of precision. To quantify the relative uncertainty of bias, we calculated the mean and standard deviation of recoveries with the measurement results of SRM 972a. Then, a Student t test was used to validate whether the mean recovery was significantly different from 1.0. If the recovery was significantly different from 1.0, a correction factor (1/recovery) was applied. The relative uncertainty of SRM 972a was quoted from the certificate of SRM 972a. More detailed information is available in Example A4 from EURACHEM/CITAC guide CG4. 18 Then, relative values were combined as follows: 
, about 95% coverage probability).
Statistics
Deming regression analysis, difference analysis, and error bar plot were obtained using Microsoft Office Excel 2010 (Microsoft, Redmond, WA) and R version 3.4.3 (The R Foundation for Statistical Computing, Vienna, Austria). The trueness verification and measurement uncertainty were calculated using Excel 2010 in accordance with CLSI guideline EP15-A3 17 and EURACHEM/ CITAC guide CG4.
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Results
The measured levels of total vitamin D in 300 serum samples were distributed throughout the relevant biological range of concentrations. The results of Deming regression analysis results and Bland-Altman plots are shown in ❚Table 1❚ and ❚Figure 1❚. The ARCHITECT 25-OH Vitamin D assay showed equivalent results to other immunoassays, but the correlation coefficient (r = 0.8880, 0.8029) was slightly lower than the adequate correlation coefficients (r ≥ 0.975) suggested by CLSI guideline EP9-A3. In the estimation of bias, repeatedly measured results of SRM 972a are shown in ❚Figure 3❚. The ARCHITECT 25-OH Vitamin D assay passed trueness verification in L2 (bias = 0.7 ng/mL) but showed statistically significant bias in L1, L3, and L4. ELECSYS Vitamin D Total showed acceptable bias in only L2 (bias = 0.4 ng/mL), and the bias of ADVIA Centaur Vitamin D Total was not statistically significant in all levels of SRM 972a. By combining the results of the commutability test and trueness verification, we finally selected SRM 972a L2 as the adequate standard material to calculate the measurement uncertainty.
The uncertainty components and results are summarized in Table 1 . All three immunoassays showed almost 100% recovery, and there was no need to calibrate bias statistically. The ARCHITECT 25-OH Vitamin D assay showed the lowest relative measurement uncertainties of precision and bias among tested immunoassays, and the expanded uncertainty of the ARCHITECT 25-OH Vitamin D assay (4.2%) was lower than the Roche and Siemens immunoassays (8.2% and 15.6%, respectively).
Discussion
The relationship between vitamin D and various diseases has been reported in several publications, [19] [20] [21] and many laboratories routinely perform vitamin D testing. In response to this demand, many laboratories have routinely performed vitamin D testing, and the performance of the vitamin D test itself has become a very important factor in measuring the concentration of vitamin D. However, differences in the results of each laboratory have been reported in studies, and these differences would be caused by the degree of cross-reactivity that varies according to the antibody used. 6, 22 Due to this discordance between assays, VDSP was conducted under the CDC in the United States to standardize vitamin D measurement and promote standardized 25(OH) D measurement by assay manufacturers and clinical and research laboratories. 23 In keeping with the need for standardization, Abbott has released a restandardized ARCHITECT 25-OH Vitamin D assay that meets the VDSP criteria and is traceable to the reference methods. 24 These improvements would be expected to present more precise and reliable results compared with the former version and other immunoassays.
In the Korean population, our study revealed that total vitamin D concentrations measured by the new ARCHITECT 25-OH Vitamin D assay showed equivalent results to the other two immunoassays (see Figure 1 and Table 1 ). However, the correlation coefficients between assays were slightly low, and the overall correlations could not be considered adequate like a previous study. 13 This disagreement has been reported to be due to differences in cross-reactivity among immunoassays to various vitamin D metabolites and the amount and polymorphism of vitamin D binding protein (DBP) present in the blood. the VDSP procedures, 24 there is still discordance among immunoassays, and the standardization of total vitamin D measurements has not yet been completed.
In the commutability study, all three immunoassays showed relatively good correlation to the reference method, while ELECSYS Vitamin D Total and ADVIA Centaur Vitamin D Total showed lower results than those of the reference method (see Figure 2) . Among the four levels of SRM 972a, L1 and L3 were also verified for commutability in certain tests while only L2 passed the commutability verification of all three immunoassays (see Figure 3) . For ADVIA Centaur Vitamin D Total, all levels of SRM 972a passed the trueness verification, but we could not determine whether the bias was truly significant because the repeated measurement results were very widely scattered. In L4, ELECSYS Vitamin D Total showed an increased result that would have originated from the cross-reactivity of the vitamin D epimer. 7 The first step for quantification of the measurement uncertainty is defining measurands, 25, 26 3 11,12 or a matrix effect. When considering all of these, we had concluded that the L2 of SRM 972a would be the best candidate for quantifying the measurement uncertainty of total vitamin D concentration.
Regarding comparison of the measurement uncertainties of three immunoassays, the ARCHITECT 25-OH Vitamin D assay had superior performance compared with the other two immunoassays ❚Table 2❚. Under the same condition, the ARCHITECT 25-OH Vitamin D assay showed more precise and accurate results than other two assays, and there was about 4.2% of expanded uncertainty around 20 ng/mL of the total vitamin D concentration. Our result was about two times higher than the result of previously reported literature (1.72%). 4 However, the result from the previous report was calculated using only precision profiles (within-run variation and between-run imprecision), and this calculation would be inappropriate. It is essential that traceability to a defined reference should be estimated in the quantification of the measurement uncertainty, 18, 25, 28 and skipping this step would not reflect the measurement uncertainty that arises during routine measurement procedures.
In conclusion, the ARCHITECT 25-OH Vitamin D assay is well standardized with the reference method and expected to be useful for the accurate and precise measurement of total vitamin D in clinical practice. However, cross-reactivity among vitamin D metabolites still exists among immunoassays, and we have not yet reached standardization of total vitamin D measurements. Therefore, the test results may show discrepancies among different assays, which leads to attention for clinicians in comparison of the results from different total vitamin D measurement systems. 
